Status:
RECRUITING
A Comparative Study of MRI and Ultrasound for Detection of Primary Hepatocellular Carcinoma, Body Composition and Risk Factors for Decompensation in Liver Cirrhosis
Lead Sponsor:
Mattias Ekstedt
Collaborating Sponsors:
Antaros Medical
Amra Medical AB
Conditions:
Liver Cirrhoses
Hepatocellular Carcinoma (HCC)
Eligibility:
All Genders
18+ years
Brief Summary
DETECT-HCC-ESLD is a prospective multicenter study designed to examine early detection and risk stratification of hepatocellular carcinoma (HCC) in individuals with advanced liver disease. Adults with...
Eligibility Criteria
Inclusion Criteria:
- Patients with liver cirrhosis, according to clinical practice. Based on criteria such as elastography, symptoms, biopsy, or radiology.
- Age ≥18 years ≤ 84
- Written informed consent from the participant
Exclusion Criteria:
- Contraindications for MRI (ferrrous material, claustrophobia)
- Pregnancy
- Diagnosis of primary sclerosing cholangitis (PSC)
- Vascular liver disease
- Congenital liver fibrosis
- Previous diagnosis of hepatic carcinoma (HCC)
- Previous liver transplant
Key Trial Info
Start Date :
December 18 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2031
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT07291141
Start Date
December 18 2025
End Date
December 1 2031
Last Update
December 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of gastroenterology and hepatology, University hospital in Linköping
Linköping, Select A State Or Province, Sweden, S-58931